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ABSTRACT
Most patients with hepatocellular carcinoma (HCC) are diagnosed at an advanced stage of 
disease. Until recently, systemic treatment options that showed survival benefits in HCC 
have been limited to tyrosine kinase inhibitors, antibodies targeting oncogenic signaling 
pathways or VEGF receptors. The HCC tumor microenvironment is characterized by a 
dysfunction of the immune system through multiple mechanisms, including accumulation 
of various immunosuppressive factors, recruitment of regulatory T cells and myeloid-derived 
suppressor cells, and induction of T cell exhaustion accompanied with the interaction 
between immune checkpoint ligands and receptors. Immune checkpoint inhibitors (ICIs) 
have been interfered this interaction and have altered therapeutic landscape of multiple 
cancer types including HCC. In this review, we discuss the use of anti-PD-1, anti-PD-L1, 
and anti-CTLA-4 antibodies in the treatment of advanced HCC. However, ICIs as a single 
agent do not benefit a significant portion of patients. Therefore, various clinical trials are 
exploring possible synergistic effects of combinations of different ICIs (anti-PD-1/PD-L1 and 
anti-CTLA-4 antibodies) or ICIs and target agents. Combinations of ICIs with locoregional 
therapies may also improve therapeutic responses.
Keywords: Carcinoma, hepatocellular; Immune checkpoint inhibitor; Therapeutics
INTRODUCTION
Hepatocellular carcinoma (HCC) is one of the most frequently diagnosed cancers and is a 
leading cause of cancer-related death. Cirrhosis induced by infection, such as by hepatitis 
B or C virus, is the principal cause of HCC. Other factors, e.g., alcohol, drugs, autoimmune 
hepatitis, and non-alcoholic fatty liver disease are also associated with HCC development. 
The incidence of HCC is gradually increasing worldwide despite the development of 
potent antiviral agents (1-3). Chronic inflammation and subsequent fibrosis can induce the 
development of HCC; inflammation also results in increased tumor immunogenicity.
In the early stages of HCC, curative treatment is possible. However, 70%–80% of patients 
are diagnosed with advanced-stage HCC (4). Sorafenib is the first-line systemic therapy for 
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patients with Child-Pugh A cirrhosis and Barcelona clinic liver cancer-stage C (5). Sorafenib 
is an oral multi-tyrosine kinase inhibitor that targets a number of signaling pathways, such 
as the pathway centered on VEGF (6). Lenvatinib is an alternative first-line therapy and is 
non-inferior to sorafenib (5,7). Until 2017, there was no second-line treatment for patients 
in whom sorafenib treatment failed. Regorafenib and cabozantinib are systemic therapies 
that have recently been used as second-line treatments (8,9). Ramucirumab after sorafenib 
in patients with advanced HCC and increased α-fetoprotein showed improved overall survival 
compared with placebo group (10). However, improvements in the overall survival rate have 
been unsatisfactory. Clearly, new approaches for HCC remain necessary.
Recent advances in molecular and tumor biology have dramatically changed the paradigm 
of cancer treatment. The development of immune checkpoint inhibitors (ICIs) was clinical 
breakthrough. Two major targets of immunotherapy are CTLA-4 (also known as CD152) 
and PD-1 with PD-L1. These molecules inhibit T cell activation and promote a state of T cell 
dysfunction known as T cell exhaustion (11). ICIs, such as anti-CTLA-4 (e.g., ipilimumab, 
tremelimumab), anti-PD-1 (e.g., nivolumab, pembrolizumab), and anti-PD-L1 (e.g., 
durvalumab, atezolizumab) antibodies, are currently approved for several types of hematologic 
and solid malignancies. HCC occurs in the context of inflammatory environments. Numerous 
studies have demonstrated the role of immune tolerance in the development of this cancer, 
suggesting that suppression of ICIs may be an effective treatment strategy (12). In this review, 
we discuss the current status and future directions of ICIs for HCC (Table 1).
IMMUNOLOGY IN HCC
The liver receives blood from hepatic artery and portal vein, enabling it to detect and 
initiate immunological responses against viruses, tumors, and parasites (13). However, 
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Table 1. Clinical trials associated with ICIs in hepatocellular carcinoma
Drug name Trial name Phase Line of therapy Design NCT number Status
Anti-PD-1
Nivolumab CheckMate 040 I/II 1L/2L Nivolumab vs. sorafenib NCT01658878 Completed
CheckMate459 III 1L Nivolumab vs. sorafenib NCT02576509 Completed
- Ib/II 2L Nivolumab+galunisertib  
(TGF-β receptor I kinase inhibitor)
NCT02423343 Recruiting
Pembrolizumab KEYNOTE-224 II 2L Pembrolizumab NCT02702414 Completed
KEYNOTE-240 III 2L Pembrolizumab vs. placebo NCT02702401 Recruiting
- I 2L Pemrolizumab+lenvatinib NCT03006926 Recruiting
Tislelizumab RATIONALE-301 III 1L Tislelizumab vs. sorafenib NCT03412773 Recruiting
Camrelizumab - II/III 2L Camrelizumab NCT02989922 Recruiting
- II 1L/2L Camrelizumab+apatinib vs. Camrelizumab+FOLFOX4 NCT03092895 Recruiting
Sintilimab ORIENT-32 III 1L Sintilimab+bevacizumab (VEGF Ab) vs. sorafenib NCT03794440 Recruiting
Anti-PD-L1
Durvalumab HIMALAYA III 1L Durvalumab+tremelimumab (CTLA-4 Ab) vs. 
durvalumab
NCT03298451 Recruiting
- II 1L/2L Durvalumab; tremelimumab; 
durvalumab+tremelimumab
NCT02519348 Recruiting
- I 2L Durvalumab+ramucirumab (VEGFR2 inhibitor) NCT02572687 Recruiting
Atezolizumab - I 1L Atezolizumab+bevacizumab NCT02715531 Recruiting
- III 1L Atezolizumab+bevacizumab vs. sorafenib NCT03434379 Recruiting
Avelumab - I 1L Avelumab+axitinib (tyrosine kinase inhibitor) NCT03289533 Recruiting
Anti-CTLA-4
Tremelimumab - II 2L Tremelimumab (HCV) NCT01008358 Completed
Ipilimumab - II Neoadjuvant Ipilimumab+nivolumab vs. nivolumab NCT03222076 Recruiting
1L, first line; 2L, second line; HCV, hepatitis C virus.
the inflammatory response causes hepatocellular DNA damage, promotes immune 
tolerance, and confers transformed hepatocytes to evade host immune surveillance, which 
cooperatively contribute to initiation and progression of HCC (14,15). Furthermore, the 
immunosuppressive tumor microenvironment mediates HCC immune tolerance and evasion 
(16,17). HCC development and progression involves the dysfunction of various human 
immune components, including immune cells and cytokines involved in HCC proliferation, 
invasion, and drug resistance (Fig. 1) (18). The infiltrating myeloid-derived suppressor 
cells and lower numbers of tumor-infiltrating lymphocytes in fibrotic HCC tissue cause 
damage to effector T cells, reduction of NK cell cytotoxicity, and activation of phenotypes 
associated with aggressive tumorigenicity (19,20). The recruitment of myeloid-derived 
suppressor cells by tumor-derived TGF-β selectively suppresses the effector function of T 
cells, diminishes metabolic fitness for T cells, and eventually leads to T cell apoptosis (21). 
Moreover, tumor-associated macrophages and neutrophils activated by TGF-β facilitate 
tumor growth, metastasis, and resistance to sorafenib. In addition, they induce immune 
tolerance through nuclear factor kappa-light-chain-enhancer of activated B cells signaling 
(22,23). A positive feedback loop triggering immune evasion occurs when secretion of 
HCC-derived cytokine (e.g., chemokine C-C motif ligand2, interleukin-4, interleukin-13, 
and C-X-C motif chemokine 12) induces differentiation of tumor-associated macrophages 
and activation of tumor-associated neutrophils. These effects result in further recruitment of 
tumor-associated macrophages and tumor-infiltrating regulatory T cells, as well as apoptosis 
of cytotoxic T lymphocytes and fatigue of anti-tumor immunity via interleukin-10 (24,25). 
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Figure 1. Schematic diagram of T cell Interaction with hepatocellular tumor cells and dendritic cells.
In addition, pro-angiogenic cytokine VEGF is up-regulated by hypoxia inducible factor-
depending pathway in the hypoxic tumor environment, which affects immune suppression 
in the tumor microenvironment through expressing higher levels of pro-inflammatory 
cytokines and immunosuppressive mediators (26). NK cells, as modulators of the balance 
between immune defense and tolerance in the liver, are directly and indirectly affected by 
the tumor microenvironment. Hypoxic stress and expression of α-fetoprotein in HCC tissue 
result in suppression of interleukin-12 secretion from dendritic cells, activating receptors on 
NK cells and causing NK cell dysfunction (27,28). Recent studies also indicate that HCC-
associated fibroblast-derived indoleamine-2,3-dioxygenase and prostaglandin E2 inhibit 
secretion of tumor necrosis factor-alpha and interferon-gamma by NK cells, resulting in 
persistent fibrosis in HCC and tumor cell immune evasion (29,30). Thus, there are multiple 
mechanisms by which the intratumoral accumulation of immunosuppressive cells and 
activation of an inhibitory immune network in the tumor microenvironment induce cancer 
stem cell-like characteristics and sustain HCC carcinogenesis (31,32).
CURRENT STATUS OF ICIS IN HCC
Anti-PD-1
Nivolumab
Nivolumab (Opdivo®), a fully humanized IgG4 anti-PD-1 monoclonal Ab, was approved by 
the Food and Drug Administration (FDA) on September 23, 2017, for patients with HCC who 
experienced sorafenib treatment failure. The CheckMate 040 trial was a phase I/II, open label, 
noncomparative, dose escalation and expansion trial for patients with advanced HCC and variety 
of underlying chronic liver diseases (33). The efficacy of nivolumab as a first-line treatment was 
evaluated in patients with advanced HCC who were treatment-naive or as a second-line treatment 
in patients on sorafenib with disease progression. Patients were treated with nivolumab at 
0.1–10 mg/kg once every 2 wk (dose-escalating cohort) or at a dose of 3 mg/kg once every 2 wk 
(expansion cohort). In this trial, 46 (96%) of 48 patients discontinued treatment in the dose-
escalation phase, 42 (88%) due to disease progression. The objective response rate was 20% (95% 
confidence interval [CI], 15%–26%) in patients treated with nivolumab 3 mg/kg in the dose-
expansion phase and 15% (95% CI, 6%–28%) in the dose-escalation phase. The most common 
treatment-related adverse events were fatigue, rash, pruritus, and an increase in liver enzyme 
levels. Grade 3/4 adverse events (e.g., adrenal insufficiency, diarrhea, hepatitis, and acute kidney 
injury) occurred in 12 of 48 patients. The baseline tumor cell expression of PD-L1 did not have an 
obvious effect on the response rate. That study revealed the therapeutic potential of nivolumab, 
showing favorable efficacy and good safety in patients with HCC who had few treatment options. 
Regrettably, the CheckMate 459 trial, a randomized phase III study evaluating nivolumab versus 
sorafenib as a first-line treatment in patients with unresectable HCC, did not achieve significance 
for its primary endpoint of overall survival as defined in the pre-specified analysis plan (hazard 
ratio [HR]=0.85; 95% CI=0.72–1.02; p=0.075) (34). Although the results failed to meet the 
predefined threshold of statistical significance because p-value for overall survival of this trial 
is borderline, there was a clear trend suggestive of improved overall survival for patients treated 
with nivolumab compared to sorafenib. A phase I/II trial of nivolumab, ipilimumab, and their 
combination at different doses and intervals is ongoing (35).
Pembrolizumab
Pembrolizumab (Keytruda®) is an IgG4/κ isotype humanized monoclonal Ab targeting 
the PD-1 receptor in immune cells. Pembrolizumab was first approved for the treatment 
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of metastatic melanoma, metastatic non-small-cell lung cancer, recurrent or metastatic 
squamous cell carcinoma of the head and neck, recurrent locally advanced or metastatic 
gastric cancer, locally advanced or metastatic urothelial cancer and classical Hodgkin 
lymphoma (36). The results of the KEYNOTE-224 trial led the FDA to approve 
pembrolizumab as s a second-line agent for treatment of HCC after sorafenib therapy on 
November 10, 2018 (37). The KEYNOTE-224 study was a non-randomized, open-label, 
multicenter phase II trial in which 104 patients were treated with intravenous pembrolizumab 
(200 mg) at 3-wk intervals for 2 years or until disease progression, or any other reason to 
stop treatment. The trial enrolled sorafenib-refractory or -intolerant patients (cohort 1) and 
patients with no history of systemic treatment (cohort 2) (37). The objective response rate 
was 17% (complete, 1%; partial, 16%). Forty-six (44%) patients had stable disease, while 34 
(33%) had progressive disease. However, serious adverse events occurred in 15% of patients. 
One died due to treatment-related ulcerative esophagitis.
The phase III KEYNOTE-240 trial is a confirmatory trial for pembrolizumab. Pembrolizumab 
was granted an accelerated approval in November 2018 for use in patients with HCC who 
were previously treated with sorafenib, based on data from the phase II KEYNOTE-224 trial. 
A total of 413 patients with advanced HCC who had previously received systemic therapy 
were randomized to receive pembrolizumab plus best supportive care or placebo plus best 
supportive care (38). Although results from the final analysis showed that improved overall 
survival when compared with placebo, the differences did not reach statistical significance 
per predefined criteria (HR=0.781; 95% CI=0.611–0.998; p=0.0238). In addition, patients 
treated with pembrolizumab exhibited improvement in progression-free survival, but this 
difference also failed to meet predefined threshold for significance. A phase III trial involving 
5 Asian countries is underway (KEYNOTE-394, NCT03062358) (39).
Tislelizumab
Tislelizumab (BGB-A317) is an anti-PD-1 Ab undergoing development by BeiGene (Beijing, 
China). Its safety was confirmed in a phase I trial involving 61 patients with cancers, 
including HCC. The RATIONALE-301 randomized phase III trial of tislelizumab versus 
sorafenib as the first-line regimen is ongoing (NCT03412773) (40). Patients were treated with 
tislelizumab 200 mg intravenously every 3 wk. The primary endpoint is overall survival and 
the secondary endpoint is non-inferiority of tislelizumab compared to sorafenib.
Camrelizumab
Camrelizumab (SHR-1210) is a fully humanized anti-PD1 IgG4 monoclonal Ab undergoing 
development by Incyte (Wilmington, DE, USA) and Jiangsu HengRui (Lianyungang, China). 
A phase I trial confirmed its safety in 58 patients with solid cancers (41). A phase II/III trial 
is underway, and involves patients who failed to respond or were intolerant to prior systemic 
treatment (NCT02989922) (42). Camrelizumab was administered intravenously at 3 mg/kg on 
day 1 every 2 wk (cohort 1) with the same dose every 3 wk (cohort 2). According to the interim 
results of the phase II trial, the objective response rate was 13.8% (95% CI, 9.5%–19.1%) and 
6-month overall survival rate was 74.7% (95% CI, 68.3%–79.9%).
Sintilimab
The anti-PD1 Ab, sintilimab, is undergoing a phase III trial. The ORIENT-32 study 
(NCT03794440) is a randomized, open-label, multicenter trial in China of sintilimab and 
bevacizumab (anti-VEGF Ab, IBI-305) versus sorafenib as a first-line treatment. Patients are 
treated with sintilimab (200 mg) and bevacizumab (15 mg/kg) intravenously on day 1 every 3 wk.
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Durvalumab (MEDI4736) is an anti-PD-L1 Ab undergoing development by MedImmune/
AstraZeneca (Cambridge, UK). Durvalumab has been approved for locally advanced or 
metastatic urothelial carcinoma. A phase I/II trial of durvalumab monotherapy for solid 
cancers, including HCC, showed a 10% response rate and a median survival duration 
of 13.2 months in patients with HCC (43). A phase I/II study evaluating a combination 
of durvalumab, and tremelimumab (an anti-CTLA-4 Ab) confirmed its safety (44). No 
unexpected side effects of durvalumab and tremelimumab were observed in patients with 
unresectable HCC. A phase III trial of durvalumab plus tremelimumab combination therapy 
as a first-line regimen is ongoing (HIMALAYA study, NCT03298451) (45). The trial is a 4-arm 
comparing patients receiving durvalumab monotherapy, durvalumab plus tremelimumab 
combination therapy (regimens 1 and 2), and sorafenib monotherapy. The primary endpoint 
of the study is overall survival; study completion is anticipated in 2020.
Atezolizumab
Atezolizumab (MPDL3280A) is an anti-PD-L1 Ab undergoing development by Roche 
(Basel, Switzerland). Atezolizumab has been proven effective for locally advanced or 
metastatic urothelial carcinoma and metastatic non-small-cell lung cancer. A phase I trial 
of atezolizumab plus bevacizumab (anti-VEGF Ab) therapy is ongoing (46). According to the 
interim results, the response rate at presentation was 32%, based on the Response Evaluation 
Criteria in Solid Tumors (RECIST) criteria. Recently, the phase III IMbrave150 study 
found that combined treatment with atezolizumab and bevacizumab was associated with 
statistically significant improvements in both overall survival and progression-free survival, 
compared with sorafenib, in patients with unresectable HCC who had not received previous 
systemic therapy. Bevacizumab presumably enhances the ability of the PD-L1 inhibitor to 
restore antitumor immunity. An open-label, randomized phase III trial focusing on survival 
in patients receiving atezolizumab plus bevacizumab therapy and sorafenib monotherapy as 
first-line regimens is underway (NCT03434379) (47). Patients receive 1,200 mg atezolizumab 
plus 15 mg/kg bevacizumab, both administered intravenously, on day 1 of each 21-day cycle. 
FDA grants breakthrough therapy designation for atezolizumab/bevacizumab combination as 
the first-line treatment for advanced or metastatic HCC last year.
Avelumab
Avelumab (MSB0010718C) is an anti-PD-L1 Ab undergoing development by Merck KGaA 
(Darmstadt, Germany), Pfizer (New York, NY, USA) and Eli Lilly (Indianapolis, IN, USA). 
Avelumab plus axitinib (AG-013736) is undergoing a phase I trial of safety and tolerability 
(NCT03289533). Patients will receive avelumab 10 mg/kg every 2 wk in combination with 
axitinib 5 mg twice a day.
Anti-CLTA-4
Tremelimumab
Tremelimumab (CP 675206) is a CTLA-4 blocking monoclonal Ab undergoing development 
by MedImmune/AstraZeneca. The first small phase II clinical trial of tremelimumab 
monotherapy for patients with HCC and chronic hepatitis C virus infection has been 
conducted (48). Tremelimumab at 15 mg/kg intravenously every 90 days was administered 
until tumor progression or severe toxicity; partial response rate was 17.6%, disease control 
rate was 76.4%, and the time to progression was 6.48 months (95% CI, 3.95–9.14 months). 
Although a significant proportion (42.9%) of patients in Child-Pugh stage B were included 
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in the study, the safety profile of treatment was also acceptable. As mentioned above, a phase 
III study of efficacy and safety of durvalumab (anti-PD-L1) plus tremelimumab combination 
therapy and durvalumab monotherapy versus sorafenib is ongoing.
Tremelimumab combined with tumor ablation was evaluated in a second small pilot 
study (49). Locoregional therapy was expected to have a synergistic effect by inducing 
immunogenic tumor cell death. A confirmed partial response was achieved in 26.3% of 
patients. This proof-of-concept study demonstrated that immunotherapy in combination 
with tumor ablation could be used as treatment for patients with advanced HCC.
Ipilimumab
Ipilimumab (YERVOY®) is an anti-CTLA-4 Ab undergoing development by Bristol-Myers 
Squibb (New York, NY, USA)/Ono (Osaka, Japan). The CheckMate 040 study includes 
evaluation of nivolumab plus ipilimumab in a subcohort of sorafenib-treated patients 
(NCT01658878). Preliminary results showed an objective response rate of 31%, with a 
median duration of response of 17 months. Two other clinical studies of nivolumab plus 
ipilimumab as a neoadjuvant therapy are ongoing. One is a randomized phase II trial in 
the US comparing nivolumab monotherapy with nivolumab plus ipilimumab combination 
therapy (NCT03222076); the other is a planned phase II trial in Taiwan and will evaluate the 
combination therapy alone (NCT03510871).
OTHER IMMUNOTHERAPIES
T cell immunoglobulin and mucin-domain containing-3 is a transmembrane protein 
expressed by CT4+ Th1 cells and CD8+ Tc1 (cytotoxic) cells (50). A phase II trial of an anti-T 
cell immunoglobulin and mucin-domain containing-3 Ab (TSR-022) and anti-PD-1 (TSR-042) 
Ab for HCC is planned (NCT03680508). TGF-β is involved in induction of maintenance of 
regulatory T cells. A phase I trial of anti-TGF-β monoclonal Ab NIS793 and PD-1 inhibitor 
spartalizumab for advanced malignancies, including HCC, is underway (NCT02947165). Anti-
TGF-β Ab is administered every 2 or 3 wk and anti-PD-1 Ab is administered every 3 or 4 wk.
Cellular immunotherapies, such as chimeric antigen receptor T cells, reportedly benefit 
patients with hematologic malignancies (51). Few studies have evaluated the efficacies of 
cellular immunotherapies against solid cancers, such as HCC. In the recent phase 3 trial, 
adjuvant immunotherapy with activated cytokine-induced killer cells prolonged recurrence-
free and overall survival of patients who underwent curative treatment for HCC (52). clinical 
trial of autologous T cell receptor-engineered T cells that recognize alpha-fetoprotein, 
involving patients with HCC and lung cancer, is underway (NCT03441100). Finally, a trial 
involving T cells that recognize glypican-3 (glypican-3-specific chimeric antigen receptor 
expressing T cells) is now recruiting patients (NCT02905188). Glypican-3 is a membrane 
factor expressed by most HCC cells.
ICIS-BASED COMBINATION THERAPY
Because HCC has various causes and uses numerous mechanisms to evade the immune 
system, an attractive therapeutic approach involves combining different treatment 
mechanisms. Potential synergistic combinations include two ICIs and ICIs with conventional 
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therapies (e.g., transarterial chemoembolization, transarterial radioembolization, radiation 
therapy, and targeted therapies). Table 2 summarizes the results of studies associated with 
ICI-based combination therapies.
Combinations of two ICIs
Combinations of two ICIs are considered promising because they can target multiple 
mechanisms. The high efficacy of combination therapy has been proven in other solid 
tumors (53). Targeting the PD-1/PD-L1 pathway alone might not inhibit development of 
the immunosuppressive microenvironment if the required CD8+ T cells are not adequately 
represented in the tumor microenvironment. However, simultaneous inhibition of the CTLA-
4 pathway might increase the number of activated CD8+ T cells in lymph nodes; this would be 
followed by an increase in the number of activated CD8+ T cells infiltrating tumor tissue and 
an enhancement of their antitumor effects. As stated above, combinations of durvalumab 
plus tremelimumab (NCT03298451) and nivolumab plus ipilimumab (NCT01658878, 
NCT03222076, NCT03510871) are examples of possible therapies.
ICIs and angiogenesis inhibitors
HCC is a highly vascularized tumor with predominantly arterial blood flow. Thus, 
angiogenesis inhibitors are good options for combination treatment of HCC. Proangiogenic 
growth factors, which are mainly produced by tumor cells, tumor-associated macrophages, 
and tumor-associated fibroblasts, include VEGF-A, platelet-derived growth factor, IGF-1, 
and TGF-β (54). Atezolizumab plus bevacizumab (NCT03434379), pembrolizumab plus 
lenvatinib, camrelizumab plus apatinib, and avelumab plus axitinib are representative 
combinations of ICIs and angiogenesis inhibitors. Atezolizumab plus bevacizumab 
was discussed earlier in this review. A phase I trial for pembrolizumab plus lenvatinib 
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Table 2. Summary of clinical trials of ICIs-based combination treatment in hepatocellular carcinoma
Characteristic Phase Line of 
therapy
Treatment No. of 
patients
Results
Combination of 2 ICIs
Nivolumab+ipilimumab (62) II 2L (A) Nivolumab 1 mg/kg+ipilimumab 3 mg/kg Q3W 
(4 doses) or (B) nivolumab 3 mg/kg+ipilimumab 
1 mg/kg Q3W (4 doses), each followed by 
nivolumab 240 mg Q2W, or (C) nivolumab 3 mg/kg 
Q2W+ipilimumab 1 mg/kg Q6W
148 (A) ORR: 32%, CR: 8%, PR: 8%, DCR: 
54%, mOS: 23 months or (B) ORR: 32%, 
CR: 6%, PR: 24%, DCR: 43%, mOS: 12 
months or (C) ORR: 31%, CR: 0%, PR: 
31%, DCR: 49%, mOS: 13 months
Durvalumab+tremelimumab (44) I/II 1L/2L 11 HBV positive, 9 HCV positive, 20 uninfected 40 ORR: 15%, CR+PR: 20%, DCR16: 57.5%
ICIs+angiogenesis inhibitors
Atezolizumab+bevaxizumab (63) III 1L (A) Atezolizumab 1,200 mg IV Q3W+bevaxizumab 15 
mg/kg IV Q3W or (B) sorafenib 400 mg BID
501 (A) mOS: NA, mPFS: 6.8 months
(B) mOS: 13.2 months, mPFS: 4.3 months
Pembrolizumab+lenvatinib (64) Ib 1L Lenvatinib (BW ≥60 kg: 12 mg/day; <60 kg: 8 mg/
day QD) and pembrolizumab (200 mg IV Q3W)
67 ORR: 44.8%, CR: 6.0%, PR: 26%, SD: 
37.3%, PD: 9.0%
Avelumab+axitinib (56) I 1L Avelumab 10 mg/kg IV Q2W+axitinib 5 mg orally BID 22 ORR: 31.8%, mPFS: 3.8 months, 6-month 
PFS: 30.9% (mRECIST)
Camrelizumab+apatinib (57) Ib 2L Camrelizumab 200 mg every 2 wk and apatinib 
125–500 mg once daily
16 PR: 44.4%, ORR: 50%, DCR: 93.8%, 
mPFS: 5.8 months
ICIs+locoregional therapy
Tremelimumab+tumor ablation (49) III 1L/2L Tremelimumab (3.5 and 10 mg/kg IV) every 4 wk for 
6 doses, followed by 3-monthly infusions. On day 
36, patients underwent ablation
32 6-month PFS: 57.1%, 12-month PFS: 33.1%, 
mTTP: 7.4 months, mOS: 12.3 months
ICIs+yttrium-90 radioembolization (65) NA 1L/2L Nivolumab alone or ipilimumab and nivolumab or 
ipilimumab and nivolumab following nivolumab
26 TTP: 5.7 months, PFS: 5.7 months
1L, first line; 2L, second line; Q3W, every 3 weeks; Q2W, every 2 weeks; Q6W, every 6 weeks; ORR, objective response rate; CR, complete response; PR, partial 
response; DCR, disease control rate; mOS, median overall survival; HBV, hepatitis B virus; HCV, hepatitis C virus; IV, intravenously; PFS, progression free survival; 
mPFS, median progression free survival; TTP, time to tumor progression; mTTP, median time to tumor progression; NA, not available; mRECIST, median Response 
Evaluation Criteria in Solid Tumors; BID, twice a day; SD, standard deviation; BW, body weight; QD, once daily.
is underway. Preliminary results showed that 46% of patients with HCC exhibited a 
radiological response (55). Consequently, a phase 3 study was initiated to compare 
lenvatinib to pembrolizumab plus lenvatinib in treatment-naive patients with advanced 
HCC (NCT03713593). A phase Ib trial of avelumab plus axitinib in 22 naive patients with 
HCC showed 13.6% and 31.8% objective response rates according to RECIST and mRECIST 
criteria, respectively (56). Camrelizumab plus apatinib showed that 50% of patients with 
HCC achieved a partial response (57). Trials of nivolumab plus bevacizumab (NCT03382886), 
nivolumab plus lenvatinib (NCT03418922), and pembrolizumab plus lenvatinib 
(NCT03713593) are underway.
Combinations of ICIs and locoregional therapy
Several trials are evaluating ICIs as (neo)adjuvant setting following by curative resection of 
ablation, such as nivolumab versus placebo following resection or ablation (NCT03343458) 
and the MK-3475-937/KEYNOTE-937 trial with pembrolizumab (NCT03867084). 
Tremelimumab combined with tumor ablation is a potential treatment option for patients 
with advanced HCC (49).
Transarterial chemoembolization is associated with enhanced spread of tumor-associated 
antigens and an increase in VEGF. A study of transarterial chemoembolization plus 
nivolumab is underway (NCT03143270). More complex approaches have recently been 
proposed, including those used in the LEAP-01 study (chemoembolization combined 
with pembrolizumab and lenvatinib, NCT03713593) and the EMERALD-1 study 
(chemoembolization combined with durvalumab and bevacizumab, NCT03778957). 
Transarterial radioembolization also promotes radiation-induced tumor damage similar to 
that induced by stereotactic radiation therapy (58). Several phase I and II studies combining 
locoregional therapy with ICIs are expected to begin soon (NCT02837029, NCT03033446, 
NCT03099564, and NCT03380130).
CONCLUSIONS AND FUTURE PERSPECTIVES
Sorafenib and lenvatinib are currently the first-line agents for advanced HCC. However, 
the prognosis for advanced HCC remains unsatisfactory. ICIs might improve the prognosis 
of patients with advanced HCC. Recent data have shown that immunotherapies enhance 
survival and are safe, but their effects are limited. Combination therapies using ICIs with 
other agents are expected to overcome tumor-induced immunosuppression. Various 
combinations of immunotherapies are undergoing trials; the results are eagerly anticipated.
In addition, it is not yet possible to determine which patients can be treated effectively with 
immunotherapy. High expression of PD-L1 is reportedly associated with poor outcome in 
patients with HCC (59). However, the predictive role of PD-L1 expression in HCC patients 
treated with ICIs is unclear. In addition, investigating noninvasive biomarkers predicting 
response to ICIs is warranted (60,61).
In conclusion, advances in immunotherapy have opened a new chapter in the treatment of 
HCC. However, further investigation of the immune biology of HCC is needed to facilitate 
development of more effective therapies for patients with HCC. In addition, overcoming 
issues such as the lack of biomarkers and combination therapies will improve the prognosis 
of patients with advanced HCC.
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